Evidence Explorer / Collection
INTERVENTIONS & CLINICAL QUESTIONS
The A–Z evidence index
109 records connecting a specific approach to a specific use. Open a record for its setting, result and limitations, then follow the full review or brief.
Descriptive evidence labels are attached to the named outcome. They are not formal GRADE ratings, product endorsements or individualized recommendations. Index compiled October 11, 2026.
Devices & physical care · Movement & rehabilitation · Nutrients & supplements · Botanicals & natural products · Conventional care comparator · Nutrition & hydration · Mind–body & integrative care · Clinical question overview
Devices & physical care
Cooling gloves & socks — Mixed evidence
Goal: Neuropathy prevention
Setting: Taxane chemotherapy, mainly breast cancer
Evidence: Small randomized and self-controlled studies
Finding: Some studies suggest less neuropathy; a randomized trial missed its primary sensory endpoint.
Limit: Cooling methods differ; cold intolerance and unblinded comparisons complicate interpretation.
Read the full evidence record →
Sources: self-controlled study · randomized trial
MS-0137 · Existing review indexed October 11, 2026
Handheld fan for breathlessness — Short-term randomized signal
Goal: Breathlessness
Setting: Advanced cancer and palliative care
Evidence: Small randomized trial, 40 participants
Finding: A one-point breathlessness reduction occurred in 80% with facial airflow versus 25% with leg airflow.
Limit: Short duration and subjective outcomes; sustained benefit remains uncertain.
Read the full evidence record →
Sources: randomized trial of 40 patients · 2026 systematic review and meta-analysis
MS-0132 · Existing review indexed October 11, 2026
Oral cryotherapy / ice chips — Guideline-supported settings
Goal: Mouth-sore prevention
Setting: Bolus 5-FU; high-dose melphalan before autologous transplant
Evidence: Randomized trials and MASCC/ISOO guidance
Finding: Evidence supports reducing mucositis in these specific treatment settings.
Limit: Brief cooling cannot be assumed effective with prolonged drug exposure or every regimen.
Read the full evidence record →
Sources: Cochrane review · MASCC/ISOO guideline
MS-0108 · Existing review indexed October 11, 2026
Scalp cooling — Randomized benefit for a specific goal
Goal: Hair retention
Setting: Breast cancer chemotherapy
Evidence: SCALP randomized trial
Finding: Hair preservation after four cycles: 50.5% with cooling versus 0% among evaluable controls.
Limit: Preservation meant less than 50% loss; incomplete protection and regimen-specific results.
Read the full evidence record →
Sources: 2017 SCALP trial · 2024 randomized trial
MS-0105 · Existing review indexed October 11, 2026
Movement & rehabilitation
Colorectal surgery prehabilitation — Positive complication signal
Goal: Surgical recovery
Setting: Elective colorectal cancer surgery
Evidence: PREHAB randomized trial, 251 participants
Finding: Severe complications: 17.1% versus 29.7% with standard care.
Limit: The primary walking-distance comparison was not significant; trial stopped early during COVID-19.
Read the full evidence record →
Sources: PREHAB randomized trial · 2024 systematic review
MS-0113 · Existing review indexed October 11, 2026
Exercise during ADT — Supportive randomized evidence
Goal: Strength and fatigue
Setting: Prostate cancer on androgen-deprivation therapy
Evidence: Supervised aerobic and resistance exercise trials
Finding: Trials support strength, fitness and fatigue benefits during ADT.
Limit: These results do not establish prostate cancer control or survival benefit.
Read the full evidence record →
Sources: randomized trial · trial of 57 men
MS-0130 · Existing review indexed October 11, 2026
Exercise with metastatic breast cancer — Positive randomized signal
Goal: Fatigue and quality of life
Setting: Metastatic breast cancer
Evidence: PREFERABLE-EFFECT, 357 participants
Finding: At six months, advantages of 5.3 points for physical fatigue and 4.8 for quality of life on 0–100 scales.
Limit: Modest average effects; unstable bone lesions excluded; no survival claim.
Read the full evidence record →
Sources: 2024 PREFERABLE-EFFECT randomized trial · research program
MS-0124 · Existing review indexed October 11, 2026
Lung surgery prehabilitation — Positive randomized signal
Goal: Surgical recovery
Setting: Higher-risk adults awaiting lung resection
Evidence: Multicenter randomized trial, 122 participants
Finding: Pulmonary complications: 34% with the program versus 55% with usual care; median stay 7 versus 9 days.
Limit: A combined breathing, nutrition, smoking-cessation and psychological program cannot isolate one component.
Read the full evidence record →
Sources: 2025 multicenter randomized trial · 2026 meta-analysis
MS-0136 · Existing review indexed October 11, 2026
Pelvic-floor training — Mixed rehabilitation evidence
Goal: Urinary continence
Setting: After radical prostatectomy
Evidence: Randomized trials
Finding: Structured training may accelerate continence recovery in some patients.
Limit: Long-term benefit and the best training intensity are not uniform across trials.
Read the full evidence record →
Sources: randomized trial of 97 men · more recent randomized trial
MS-0127 · Existing review indexed October 11, 2026
Strength training with lymphedema — Supportive randomized evidence
Goal: Strength and symptom management
Setting: Breast cancer survivors with stable arm lymphedema
Evidence: Randomized trial, 141 participants
Finding: Progressive training improved strength; flare-ups occurred in 14% versus 29%.
Limit: The primary limb-swelling comparison was not different; stable lymphedema was required.
Read the full evidence record →
Sources: 2009 randomized trial · systematic review in the 2019 journal collection
MS-0103 · Existing review indexed October 11, 2026
Structured exercise after colon cancer — Positive phase III evidence
Goal: Disease-free survival
Setting: Resected high-risk stage II or stage III colon cancer after chemotherapy
Evidence: CHALLENGE randomized trial, 889 participants
Finding: Five-year disease-free survival: 80.3% versus 73.9%; difference 6.4 percentage points.
Limit: Three-year supported program in a defined setting; not evidence of a universal cancer cure.
Read the full evidence record →
Sources: 2025 CHALLENGE randomized trial · ASCO’s exercise guideline
MS-0047 · Existing review indexed October 11, 2026
Nutrients & supplements
Acetyl-L-carnitine for taxane neuropathy — Harm signal
Goal: Neuropathy prevention
Setting: Women receiving adjuvant taxane chemotherapy for breast cancer
Evidence: Randomized double-blind trial; 409 evaluable participants
Read the full evidence record →
Sources: Hershman et al., 2013 randomized trial · SWOG S0715 two-year follow-up
MS-N001 · New brief; sources checked October 11, 2026
Alpha-lipoic acid for chemotherapy neuropathy — Benefit not established
Goal: Neuropathy prevention or symptoms
Setting: Chemotherapy-related neuropathy
Evidence: Randomized trial plus broader narrative review
Finding: Evidence from diabetic neuropathy does not establish benefit in chemotherapy neuropathy.
Limit: Prevention, pain relief and nerve recovery are separate endpoints; trial adherence was a limitation.
Read the full evidence record →
Sources: SYDNEY 2 · 2024 Cochrane review
MS-0038 · Existing review indexed October 11, 2026
IV vitamin C in pancreatic cancer — Investigational randomized signal
Goal: Cancer-control research
Setting: Metastatic pancreatic cancer with gemcitabine/nab-paclitaxel
Evidence: Small randomized trial; 36 randomized, 34 treated
Read the full evidence record →
Sources: 2024 randomized trial of pharmacological ascorbate · NCI: Intravenous Vitamin C (PDQ)
MS-N003 · New brief; sources checked October 11, 2026
L-glutamine in pancreatic cancer — Early-phase investigational
Goal: Cancer-control research
Setting: Advanced pancreatic cancer with gemcitabine/nab-paclitaxel
Evidence: GlutaPanc single-arm phase I; 16 evaluable
Finding: Dose-finding and response signals support further research.
Limit: No randomized chemotherapy-only comparator; cannot attribute survival to glutamine.
Read the full evidence record →
Sources: GlutaPanc phase 1 report, Nature Cancer (2026) · Published study protocol (2023)
MS-0029 · Existing review indexed October 11, 2026
Melatonin for sleep — Small randomized signal
Goal: Sleep
Setting: Selected breast cancer survivors
Evidence: Placebo-controlled trial, 95 participants
Finding: Average sleep-score improvement was 1.9 points with melatonin versus 0.1 with placebo.
Limit: Selected post-treatment population; no demonstrated recurrence or survival benefit.
Read the full evidence record →
Sources: 2014 placebo-controlled trial · September 2026 report
MS-0126 · Existing review indexed October 11, 2026
Omega-3s for weight loss — Inconsistent evidence
Goal: Weight and muscle support
Setting: Advanced cancer with wasting
Evidence: Large randomized trials; nutrition guidance
Finding: Large trials did not reliably reverse weight or lean-mass loss.
Limit: Purified EPA, enriched drinks and other omega-3 products are different interventions.
Read the full evidence record →
Sources: multicenter randomized trial · phase III trial involving 421 people with incurable cancer and wasting
MS-0107 · Existing review indexed October 11, 2026
Probiotics during pelvic radiation — Mixed, strain-specific evidence
Goal: Diarrhea prevention
Setting: Pelvic radiation
Evidence: Randomized placebo-controlled trials
Finding: Some favorable signals, but a large trial missed its overall primary endpoint.
Limit: Strain, dose and treatment setting vary; probiotics are not one interchangeable intervention.
Read the full evidence record →
Sources: double-blind randomized trial · meta-analysis of randomized trials
MS-0128 · Existing review indexed October 11, 2026
Vitamin B6 for hand–foot syndrome — No demonstrated benefit
Goal: Hand–foot syndrome prevention
Setting: Capecitabine treatment
Evidence: Placebo-controlled phase III trial and other trials
Finding: Pyridoxine did not significantly prevent moderate or severe hand–foot syndrome.
Limit: Plausibility and routine vitamin needs do not establish benefit from high doses.
Read the full evidence record →
Sources: double-blind phase 3 trial · meta-analysis
MS-0112 · Existing review indexed October 11, 2026
Vitamin D for AI joint pain — No consistent symptom benefit
Goal: Joint symptoms
Setting: Breast cancer on aromatase inhibitors
Evidence: Randomized trials
Finding: Higher vitamin D levels did not reliably prevent joint symptoms.
Limit: Correcting deficiency and protecting bone health are separate indications.
Read the full evidence record →
Sources: 2019 randomized trial · 2017 VITAL trial in women starting letrozole
MS-0059 · Existing review indexed October 11, 2026
Zinc for taste changes — No consistent benefit
Goal: Taste and appetite
Setting: Head and neck radiation
Evidence: Phase III placebo-controlled trial
Finding: The largest trial did not significantly prevent taste changes or accelerate recovery.
Limit: Small earlier studies differ; correcting deficiency is a separate question.
Read the full evidence record →
Sources: multicenter N01C4 trial · 18-patient randomized trial
MS-0135 · Existing review indexed October 11, 2026
Botanicals & natural products
American ginseng for fatigue — Conditional guideline option
Goal: Fatigue
Setting: Adults during or after cancer treatment
Evidence: N07C2 placebo-controlled trial; ASCO–SIO guideline
Finding: Primary four-week comparison was not significant; eight-week improvement was 20 versus 10.3 points.
Limit: Specific Wisconsin American ginseng preparation; no cancer-control result.
Read the full evidence record →
Sources: N07C2 randomized, double-blind trial · 2024 ASCO–Society for Integrative Oncology fatigue guideline
MS-0048 · Existing review indexed October 11, 2026
Cannabinoids for cancer pain — Benefit not established
Goal: Pain
Setting: Advanced cancer with pain despite opioids
Evidence: Nabiximols randomized trials, including phase III
Finding: Larger confirmatory trials did not meet primary pain endpoints.
Limit: Standardized THC:CBD spray evidence does not generalize to every cannabis product.
Read the full evidence record →
Sources: randomized graded-dose trial · phase 3 trial
MS-0129 · Existing review indexed October 11, 2026
Cannabinoids for refractory chemotherapy nausea — Conditional adjunctive option
Goal: Nausea and vomiting
Setting: Adults with symptoms despite guideline-based antiemetics
Evidence: ASCO cannabis and cannabinoid guideline, 2024
Read the full evidence record →
Sources: ASCO cannabis and cannabinoids guideline, 2024
MS-N012 · New brief; sources checked October 11, 2026
Curcumin for radiation skin reactions — Oral negative; topical uncertain
Goal: Radiation skin symptoms
Setting: Breast radiotherapy
Evidence: Large oral RCT; small topical studies
Finding: The large oral trial did not improve its primary dermatitis endpoint; topical pilots ask a separate question.
Limit: Oral supplements and gels cannot be treated as equivalent.
Read the full evidence record →
Sources: multicenter randomized trial, published online in December 2017 and in the 2018 journal issue · pilot placebo-controlled trial published March 27, 2025
MS-0104 · Existing review indexed October 11, 2026
Ginger for chemotherapy nausea — Mixed; positive trial signal
Goal: Acute nausea
Setting: Chemotherapy with antiemetic medication
Evidence: Randomized placebo-controlled trial
Finding: One trial found lower acute nausea severity when ginger was added to antiemetics.
Limit: Preparation, acute versus delayed symptoms and background antiemetics affect applicability.
Read the full evidence record →
Sources: randomized, double-blind trial published in 2012 · 2022 umbrella review of ginger and human health
MS-0049 · Existing review indexed October 11, 2026
Laetrile / amygdalin (“B17”) — No established efficacy; toxicity concern
Goal: Cancer-treatment claim
Setting: Patients with various advanced cancers
Evidence: NCI review, including a phase II study
Read the full evidence record →
Sources: NCI: Laetrile/Amygdalin (PDQ)
MS-N006 · New brief; sources checked October 11, 2026
Medicinal mushroom extracts — Product-specific, uncertain applicability
Goal: Adjunctive cancer-treatment research
Setting: Product-specific studies, including PSK and reishi
Evidence: NCI evidence summary of clinical and preclinical studies
Read the full evidence record →
Sources: NCI: Medicinal Mushrooms (PDQ) · NCI listing: reishi for AI-related symptoms; check current status
MS-N005 · New brief; sources checked October 11, 2026
Mistletoe extracts — Uncertain evidence
Goal: Quality of life and cancer-control claims
Setting: Multiple cancer settings; specific injectable extracts
Evidence: Heterogeneous clinical studies summarized by NCI
Read the full evidence record →
Sources: NCI: Mistletoe Extracts (PDQ)
MS-N004 · New brief; sources checked October 11, 2026
Peppermint aromatherapy for nausea — Preliminary signal
Goal: Nausea
Setting: Adults receiving chemotherapy with standard antiemetics
Evidence: Open-label, quasi-randomized controlled pilot
Read the full evidence record →
Sources: Peppermint-oil quasi-randomized pilot study
MS-N011 · New brief; sources checked October 11, 2026
St. John’s wort and irinotecan — Documented interaction
Goal: Treatment-interaction safety
Setting: People receiving irinotecan
Evidence: Small randomized crossover pharmacokinetic study
Read the full evidence record →
Sources: Mathijssen et al., 2002 interaction study · NCI: Cancer therapy interactions
MS-N002 · New brief; sources checked October 11, 2026
Tart cherry for AI joint pain — Small randomized signal
Goal: Joint pain
Setting: Nonmetastatic hormone-positive breast cancer on aromatase inhibitors
Evidence: Double-blind trial; 48 analyzed over six weeks
Finding: Mean percentage pain decrease: 34.7% versus 1.4% with placebo.
Limit: Small, short study; exclusions and industry funding warrant attention.
Read the full evidence record →
MS-0031 · Existing review indexed October 11, 2026
Conventional care comparator
Oxybutynin for hot flashes — Short-term randomized benefit
Goal: Hot flashes
Setting: Women with frequent hot flashes, many on endocrine therapy
Evidence: Placebo-controlled trial, 150 randomized
Finding: Daily episodes fell by 4.8 or 7.5 with the two doses versus 2.6 with placebo.
Limit: Only 113 evaluable for the primary outcome; six-week follow-up.
Read the full evidence record →
Sources: 2019 ACCRU trial · 2026 ASCO systematic-review abstract
MS-0125 · Existing review indexed October 11, 2026
Nutrition & hydration
Fasting around treatment — Investigational
Goal: Cancer-control and tolerability research
Setting: Selected cancer trial populations
Evidence: Small trials and conference reports
Finding: Early signals merit research; a definitive cancer-control benefit is not established.
Limit: Fasting windows and fasting-mimicking diets differ; small studies and abstract-only reports limit confidence.
Read the full evidence record →
Sources: 2026 ASCO Annual Meeting, abstract 5517 · research regimen permitted fluids and up to 350 calories daily
MS-0064 · Existing review indexed October 11, 2026
Hydration and electrolytes — Treatment-specific guidance
Goal: Correcting fluid losses
Setting: During cancer treatment
Evidence: Clinical nutrition and supportive-care guidance
Finding: Replacing dehydration can help; extra water and alkaline water have no established anticancer role.
Limit: Needs vary with losses, treatment, kidney and heart function.
Read the full evidence record →
Sources: More on when to seek care. · eviQ’s cisplatin guidance
MS-0138 · Existing review indexed October 11, 2026
Nutrition shakes — Practical nutrition guidance
Goal: Intake and weight support
Setting: Cancer-related poor intake
Evidence: Nutrition guidance and product-label comparison
Finding: The guide compares 13 formulas by calories, protein and practical features.
Limit: A label comparison does not show a brand improves cancer outcomes; formulations change.
Read the full evidence record →
Sources: NCI nutrition guidance · Ensure Original (retail)
MS-0139 · Existing review indexed October 11, 2026
Mind–body & integrative care
Acupuncture for AI joint pain — Guideline-supported option
Goal: Joint pain
Setting: Adults with aromatase-inhibitor-related joint pain
Evidence: SIO–ASCO pain guideline based on controlled studies
Read the full evidence record →
Sources: SIO–ASCO integrative pain guideline, 2022
MS-N007 · New brief; sources checked October 11, 2026
Acupuncture for dry mouth — Modest randomized benefit
Goal: Dry mouth
Setting: Head and neck cancer after radiation
Evidence: Multicenter randomized trial, 258 participants
Finding: True acupuncture improved dry-mouth scores versus oral hygiene by 6.67 points at four weeks.
Limit: The mean difference was below the prespecified 10-point threshold; sham comparison was less convincing.
Read the full evidence record →
Sources: multicenter randomized trial · 2019 randomized trial
MS-0114 · Existing review indexed October 11, 2026
CBT-I — Guideline-supported
Goal: Insomnia
Setting: Cancer survivors; adapted approaches during treatment
Evidence: Randomized trials and ESMO insomnia guidance
Finding: Structured cognitive behavioral therapy improves insomnia outcomes.
Limit: Access, delivery and active-treatment burden vary; waiting-list trials have limitations.
Read the full evidence record →
Sources: 2023 ESMO insomnia guideline · 2018 trial
MS-0060 · Existing review indexed October 11, 2026
Hypnosis for procedural pain — Conditional guideline option
Goal: Procedural pain
Setting: Adults undergoing cancer-related procedures
Evidence: SIO–ASCO integrative pain guideline
Read the full evidence record →
Sources: SIO–ASCO integrative pain guideline, 2022
MS-N009 · New brief; sources checked October 11, 2026
Massage for palliative cancer pain — Conditional guideline option
Goal: Pain and comfort
Setting: Adults receiving palliative or hospice care
Evidence: SIO–ASCO integrative pain guideline
Read the full evidence record →
Sources: SIO–ASCO integrative pain guideline, 2022
MS-N008 · New brief; sources checked October 11, 2026
Mindfulness for anxiety — Guideline-supported
Goal: Anxiety and distress
Setting: During and after cancer treatment
Evidence: Randomized trials and SIO–ASCO guidance
Finding: Structured mindfulness programs can improve anxiety symptoms.
Limit: Program design and comparators differ; no recurrence or survival conclusion.
Read the full evidence record →
Sources: 2012 randomized trial · 2023 Society for Integrative Oncology–ASCO guideline
MS-0058 · Existing review indexed October 11, 2026
Tai chi and qigong for fatigue — Guideline-supported setting
Goal: Fatigue
Setting: Adults during cancer treatment
Evidence: ASCO–SIO fatigue guideline, 2024
Read the full evidence record →
Sources: ASCO–SIO fatigue guideline, 2024
MS-N010 · New brief; sources checked October 11, 2026
Yoga after treatment — Supportive randomized evidence
Goal: Fatigue and sleep
Setting: Cancer survivors, predominantly breast cancer
Evidence: YOCAS randomized trial
Finding: Gentle instructor-led yoga improved fatigue in a survivor trial.
Limit: Fatigue was a secondary outcome; participants and programs were selected.
Read the full evidence record →
Sources: multicenter randomized trial · 2024 meta-analysis of 18 breast-cancer trials
MS-0106 · Existing review indexed October 11, 2026
Clinical question overview
Complementary nausea approaches — Narrative overview
Goal: Nausea and vomiting
Setting: During chemotherapy
Evidence: Review of several distinct approaches
Finding: Introduces ginger, aromatherapy and other adjunctive approaches.
Limit: This overview is not a systematic review or a single-intervention efficacy record.
Read the full evidence record →
MS-0109 · Existing review indexed October 11, 2026
← Return to Evidence Explorer · How to judge a study
Added October 13, 2026
- Coenzyme Q10 for cancer-related fatigue — Nutrients & supplements · Mixed / uncertain
- Clinical hypnosis for hot flashes after breast cancer — Mind–body & integrative care · Positive randomized signal
- Creatine for cancer-related wasting and muscle loss — Nutrients & supplements · No demonstrated benefit
- Topical diclofenac to prevent capecitabine hand–foot syndrome — Conventional care comparator · Mixed / uncertain
The existing acupuncture for aromatase-inhibitor joint pain record was also strengthened with trial denominators, absolute and responder effects, 52-week follow-up and safety details.
October 14 additions
- Individualized dietary counseling during radiotherapy — positive randomized signal / practical guidance.
- Neutropenic diets during leukemia treatment and stem-cell transplant — no demonstrated infection-prevention benefit.
- Soy foods after breast cancer — observationally reassuring; whole foods are not isoflavone supplements.
- Perioperative immunonutrition for gastrointestinal cancer surgery — positive randomized signal, formulation-specific.
- High-dose vitamin D with chemotherapy for metastatic colorectal cancer — phase III found no progression-free or overall-survival benefit.
- High-vegetable diet during prostate-cancer active surveillance — no demonstrated progression benefit despite changed eating behavior.
- Selenium during pelvic radiotherapy — small randomized diarrhea signal limited to documented deficiency and supervised dosing.
- Photobiomodulation for oral mucositis — positive randomized mucositis signal, protocol-specific.
- Self-acupressure for persistent fatigue after breast cancer — positive randomized fatigue signal; symptom support, not cancer treatment.
- Pomegranate products for prostate-cancer progression — placebo-controlled studies did not demonstrate cancer-control benefit.
MS-N018–MS-N027 · Added and source-checked October 14, 2026.
October 15, 2026 additions
- Black cohosh for hot flashes after breast cancer — phase III found no benefit beyond placebo; liver and product-quality cautions.
- Guarana for cancer-related fatigue — conflicting small trials and heterogeneous meta-analyses.
- Chamomile mouthwash for treatment-related oral mucositis — the largest placebo-controlled trial was negative; smaller later signals remain uncertain.
- Calendula ointment for breast-radiotherapy skin reactions — positive older randomized signal against trolamine, formulation-specific.
- Aloe vera gel for radiation dermatitis — conflicting results across radiation sites and products.
- Vitamin E for hot flashes after breast cancer — about one fewer hot flash per day; benefit was clinically minimal.
- Intravenous glutathione to prevent platinum neuropathy — positive small-trial neuropathy signal, insufficient for routine intravenous use.
- Oral L-glutamine for treatment-related oral mucositis — older negative trials and a large 2026 head-and-neck signal; regimen-specific.
- Milk thistle for chemotherapy-associated liver injury — laboratory trends without demonstrated clinical liver benefit.
- Goshajinkigan to prevent oxaliplatin neuropathy — phase III stopped early; neuropathy was more frequent with the Kampo formula.
MS-N029–MS-N038 · Added and source-checked October 15, 2026.
October 16, 2026 additions
- Structured physiotherapy after breast-cancer surgery — Movement, rehabilitation or supportive physical care · Positive randomized rehabilitation evidence.
- Exercise prehabilitation before head-and-neck chemoradiotherapy — Movement, rehabilitation or supportive physical care · Preliminary positive randomized signal.
- Supervised exercise during neoadjuvant breast chemotherapy — Movement, rehabilitation or supportive physical care · No demonstrated tumor-response benefit.
- Lesion-aware exercise with prostate-cancer bone metastases — Movement, rehabilitation or supportive physical care · Positive functional and supervised-safety signal.
- Aerobic exercise for cognitive changes during breast-cancer chemotherapy — Movement, rehabilitation or supportive physical care · Mixed randomized evidence.
- Aerobic exercise for neuropathy after ovarian-cancer chemotherapy — Movement, rehabilitation or supportive physical care · Promising secondary randomized signal.
- Manual lymph drainage to prevent arm lymphedema after breast surgery — Movement, rehabilitation or supportive physical care · No demonstrated prevention benefit.
- Preventive swallowing exercises during head-and-neck radiotherapy — Movement, rehabilitation or supportive physical care · Mixed evidence.
- Exercise during allogeneic stem-cell transplantation — Movement, rehabilitation or supportive physical care · Small randomized supportive signal.
- Intermittent aerobic exercise for insomnia during breast-cancer chemotherapy — Movement, rehabilitation or supportive physical care · Primary sleep-duration endpoint negative.
MS-N039–MS-N048 · Added and source-checked October 16, 2026.
New records added October 17, 2026
- MS-N049 — Music therapy compared with CBT for anxiety in cancer survivors
- MS-N050 — Acupuncture compared with CBT-I for insomnia in cancer survivors
- MS-N051 — Tai Chi Chih compared with CBT-I for insomnia after breast cancer
- MS-N052 — Morning bright light for fatigue during breast-cancer chemotherapy
- MS-N053 — Expressive writing for symptoms and physical quality of life in renal cell carcinoma
- MS-N054 — Mindfulness-based programs for fatigue after breast cancer
- MS-N055 — Yoga during radiotherapy for breast-cancer quality of life
- MS-N056 — Progressive muscle relaxation plus guided imagery for anxiety during chemotherapy
- MS-N057 — Dignity therapy for distress near the end of life
- MS-N058 — Meaning-centered psychotherapy in advanced cancer
MS-N049–MS-N058 · Primary sources and relevant guidance checked October 17, 2026.
Added October 18, 2026
- Acupuncture for fatigue after breast-cancer chemotherapy — promising but inconsistent
- Acupuncture for chemotherapy neuropathy — mixed; 2026 primary endpoint negative
- Acupuncture for chronic radiation dry mouth — positive versus oral hygiene; sham contrast time-dependent
- Acupuncture for chronic survivor pain — pragmatic benefit
- Electroacupuncture for hot flashes — promising phase II evidence
- P6 wristbands for chemotherapy nausea — no clear specific benefit
- Reflexology in advanced breast cancer — limited symptom/function signals
- Oral cryotherapy for mucositis prevention — regimen-specific support
- Scalp cooling for chemotherapy hair loss — effective for some regimens
- Frozen gloves and socks for taxane neuropathy — 2026 primary endpoint negative
October 19 additions
- A: Antioxidant supplements during breast-cancer chemotherapy; antioxidant vitamins during head-and-neck radiotherapy.
- B: Black salve for skin cancer.
- C: Cannabis during immune-checkpoint inhibitor therapy; chlorine dioxide/MMS for cancer; curcumin with tamoxifen.
- E: Essiac/Flor Essence for cancer.
- G: Gerson therapy and coffee enemas; grapefruit with oral anticancer medicines.
- P: Probiotic supplements during immune-checkpoint inhibitor therapy.
